Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.YOSEMITE and RHINE Investigators*(Menteş J, in Yosemite Study Group)


Menteş J.

Lancet, vol.339, no.10326, pp.741-755, 2022 (Journal Indexed in SCI Expanded)

  • Publication Type: Article / Article
  • Volume: 339 Issue: 10326
  • Publication Date: 2022
  • Doi Number: 10.1016/s0140-6736(22)00018-6
  • Title of Journal : Lancet
  • Page Numbers: pp.741-755